News
New Informative Website Launched to Help People With Oral Mucositis and Their Carers
25 January 2010.
LONDON, UNITED KINGDOM - From today, a new resource is available to
help people with Oral Mucositis:
www.mouthsmadegood.com.
Oral Mucositis (OM) is a side effect of cancer therapy and is
characterised by a red, swollen and ulcerated mouth and tongue. The
painful condition, associated with both chemo- and radiotherapy can
prevent sufferers from talking and even eating - and in severe cases
a feeding tube is sometimes necessary so the patient can get the
nutrients required to continue with the cancer therapy. In fact, in
a survey of nurses, it was identified as the most debilitating and
significant problem associated with cancer therapy.
The new site, sponsored by Caphosol® provides
detailed information about the following:
-
the condition itself - what are the symptoms and
how long will they last?
-
the type of people at risk - who is more likely
to get OM?
-
the consequences of OM
-
OM management strategies
A succinct factsheet can also be downloaded at
www.mouthsmadegood.com/managing-OM.aspx.
The site also enables sufferers and carers to
share their experiences, comment and ask questions as well as upload
their own video blog to help others in the same situation.
Finally the 'send a smile' page allows people to do just that. Add a
smile to one of a number of pictures, or upload your own and forward
to a friend to cheer them up.
Iain McGill, President Europe and International at EUSA Pharma said:
"Oral Mucositis is a particularly common and often devastating side
effect of cancer therapy. We hope we've provided a useful and
informative forum, where people can share their own insights and
help others overcome this lesser known side effect of cancer
treatment."
For more information visit
www.mouthsmadegood.com.
Caphosol® was launched in the UK during 2009 by
EUSA Pharma – a specialist pharmaceutical company focused on
in-licensing, developing and marketing late-stage oncology, pain
control and critical care products.
For product information, please contact:
Melanie Gross (Global Product Manager - Caphosol®) melanie.gross@eusapharma.com
|
